cbdMD, Inc. (NYSE American: YCBD) is a leading company in the CBD industry, known for its diverse product offerings, including Herbal Oasis THC seltzers, ATRx functional mushroom supplements, and Paw CBD. The company has been making strides in improving its financial health and market position, as evidenced by its recent earnings report and strategic initiatives.
On December 19, 2025, YCBD reported a revenue for the period of approximately $4.72 million, slightly above the estimated $4.70 million, showcasing steady growth. The company's financial performance has been on an upward trajectory, with a notable reduction in its operating loss. YCBD reported a loss from operations of $2.1 million, a significant improvement from the $3.3 million loss in fiscal 2024. This improvement is attributed to disciplined cost management and ongoing investment in quality and science.
In addition to its earnings performance, YCBD has strengthened its financial position through a $2.25 million Series C Preferred Stock private placement. The proceeds, approximately $2.1 million after expenses, will support working capital and strategic initiatives. The Series C shares offer a 10% annual dividend and conversion options, providing flexibility for investors.
YCBD maintains a relatively low debt-to-equity ratio of 0.16, indicating modest debt levels. The current ratio of 1.56 suggests good liquidity, allowing the company to cover short-term liabilities effectively. These financial metrics reflect YCBD's ongoing efforts to improve its financial health and market position.
